Bioscience

InNexus & Genhelix to combine antibody development & manufacturing effort

July 10, 2009

By Flinn Foundation

[Source: Businesswire] – InNexus Biotechnology Inc. (TSX Venture: IXS) (OTCBB: IXSBF) and Genhelix Biopharmaceutical Company announced today the signing of a Letter of Intent to set the stage for a planned strategic collaboration to focus on developing novel antibodies engineered with InNexus’ DXL™ technology.

The research and licensing agreement between the collaborators is expected to be completed later this year. InNexus will conduct preclinical development for a DXL™ therapeutic against an undisclosed target, with Genhelix providing GMP production and commercial manufacturing. DXL™ antibodies are biologics engineered with the novel ability to link with one another (self-binding) upon reaching their target, exhibiting marked enhancements for ADCC and CDC functions over the source antibody.

News of the planned alliance follows InNexus’ recently announced successful meeting with the FDA, where the agency expressed clear support for the company’s product development plans following a comprehensive review of the proposed clinical pathway for its lead preclinical candidate, DXL625 (CD20) for the prospective treatment of non-Hodgkin’s lymphoma and/or chronic lymphocytic leukemia. The agency also provided a Manufacturing Exception Approval allowing InNexus to manufacture all clinical material needed for DXL625’s Phase l human trial, in its facilities located on the campus of Mayo Clinic in Scottsdale, Arizona.

For more information: InNexus and Genhelix to Combine Antibody Development and Manufacturing Resources